Literature DB >> 2033910

Growth in children with adrenocortical tumors.

B P Hauffa1, C Roll, R Mühlenberg, W Havers.   

Abstract

Longitudinal growth was assessed in 10 children aged 0.8 to 11.8 years with adrenocortical tumors. All children had signs of androgen excess. In addition, 5 children had glucocorticoid excess, 1 child had estrogen excess. Multiple height recordings, expressed as height standard deviation score for chronological age, were available in 7 children. 5 patients in whom the tumor was successfully removed had postoperatively decreasing height standard deviation scores. 2 patients in whom tumor disease and hormone overproduction were not effectively controlled continued to show increased growth. When simultaneously present in one patient, the growth-promoting effects of androgen excess appear to override the growth-blocking properties of endogenous glucocorticoid excess. The importance of longitudinally recorded growth data for early diagnosis of an adrenocortical tumor is limited to those few children in whom hormone excess is given enough time to act on the skeleton before other tumor-related symptoms appear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033910     DOI: 10.1055/s-2007-1025405

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  3 in total

1.  Growth patterns after for virilising adrenocortical adenoma.

Authors:  B P Hauffa; C Roll; R Mühlenberg; W Havers
Journal:  Arch Dis Child       Date:  1992-11       Impact factor: 3.791

2.  Rare case of an adrenocortical neoplasm: A case report and review of literature.

Authors:  Rossella Angotti; Francesco Molinaro; Anna Lavinia Bulotta; Giovanni DI Maggio; Elisa Brandigi; Mario Messina
Journal:  Oncol Lett       Date:  2014-10-02       Impact factor: 2.967

3.  Gonadotropin-dependent pubertal disorders are common in patients with virilizing adrenocortical tumors in childhood.

Authors:  Monica F Stecchini; Zilda Braid; Candy B More; Davi C Aragon; Margaret Castro; Ayrton C Moreira; Sonir R Antonini
Journal:  Endocr Connect       Date:  2019-05-01       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.